Conference Reports for NATAP

EASL - European Association for the Study of the Liver May 7-10, 2025 Amsterdam the Netherlands Back

Linerixibat significantly improves cholestatic pruritus in PBC: results of the pivotal Phase 3 GLISTEN trial       EASL 2025 May 7-10 Amsterdam oral presentation General Session 1   Dr Gideon Hirschfield, The Autoimmune and Rare Liver Disease Programme, Toronto, on behalf of the GLISTEN Investigators